Evidence for a suppression of apoptosis in early postnatal life

References

• Kerr JFR, Wylie AH, Cume AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239–57.
   Google Scholar
• Negata S, Goldstein P The Fas Death Factor. Science 1995; 267: 1449–56.
   Google Scholar
• Watanabe-Fukunaga R, Brannan CI, Itoh N, Yonehara S, Copeland NG, Jenkins NA et al. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. J Immunol 1992; 148: 1274–9.
   Google Scholar
• Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301–5.
   Google Scholar
• Debatin K-M, Goldman CK, Waldman TA, Krammer PH. APO-1 induces apoptosis of leukemia cells from patients with ATL. Blood 1993; 81: 2972–7.
   Google Scholar
• Katsikis PI, Wunderlich ES, Smith CA, Herzenberg LA, Herzenberg LA. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med 1995; 181: 2029–36.
   Google Scholar
• Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA et al. Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med 1995; 181: 71–7.
   Google Scholar
• Arase H, Arase N, Saito T. Fas mediated cytotoxicity by freshly isolated natural killer cells. J Exp Med 1995; 181: 1235–8.
   Google Scholar
• Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ. Differential expression of Fas (CD 95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med 1996; 184: 429–0.
   Google Scholar
• Suda T, Okazaki T, Naito Y, Yokota N, Aral N, Ozaki S et al. Expression of the Fas ligand in T-cell lineage. J Immunol 1995; 154: 3806–13.
   Google Scholar
• Tanaka M, Suda T, Haze K, Nakamura M, Sato K, Kimu- ra F et al. Fas ligand in human serum. Nat Med 1996; 2: 317–22.
   Google Scholar
• Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RA. A role for CD95 ligand in preventing graft rejection. Science 1995; 377: 630–2.
   Google Scholar
• Griffith T, Brunner T, Fletcher S, Gree D, Ferguson T. Fas ligand induces apoptosis as a mechanism of immune privilege. Science 1995; 270: 1187–92.
   Google Scholar
• Nagata S. Apoptosis by death factor. Cell 1997; 88: 35565.
   Google Scholar
• Suda T, Hashimoto H, Tanaka M, Ochi T, Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes and soluble Fas ligand blocks the killing. J Exp Med 1997; 186: 2045–50.
   Google Scholar
• Grell M, Douni E, Wajant H, Löhden M, Clauss M, Maxeiner B et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 83: 793–802.
   Google Scholar
• Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 1994; 76: 959–62.
   Google Scholar
• Gearing AJH, Beckett P, Christodoulou M, Churchill M, Clements J, Davidson AH et al. Processing of tumor necrosis factor-α precursor by metalloproteinases. Nature 1994; 370: 555–7.
   Google Scholar
• Hetts SW. To die or not to die. An overview of apoptosis and its role in disease. JAMA 1998; 279: 300–7.
   Google Scholar
• Papoff G, Cascino I, Eramo A, Starace G, Lynch DH, Ru- berti G. An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 1996; 156: 4622–30.
   Google Scholar
• Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J Biol Chem 1987; 262: 6951–4.
   Google Scholar
• Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor a in vitro and in vivo. Proc Natl Acad Sci USA 1992; 89: 4845–9.
   Google Scholar
• Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998; 4: 31–6.
   Google Scholar
• Iwama H, Akutsu H, Kuretake S, Tohma J, Nakamura N. Serum concentrations of soluble Fas antigen and soluble Fas ligand in mother and newborn. Arch Gynecol Obstet 2000; 263: 108–10.
   Google Scholar
• Jacobson MD, Weil M, Raff MC. Programmed cell death in animal development. Cell 1997; 88: 347–54.
   Google Scholar
• Narayanan V Apoptosis in development and disease of the nervous system. 1. Naturally occurring cell death in the developing nervous system. Pediatr Neurol 1997; 16: 9–13.
   Google Scholar
• Lee DM, Osathanondh R, Yeh J. Localization of Bcl-2 in the human fetal mullerian tract. Fertil Steril 1998; 70: 13540.
   Google Scholar
• Brill A, Torchinski A, Carp H, Toder V. The role of apoptosis in normal and abnormal embryonic development. J Assist Reprod Genet 1999; 16: 512–19.
   Google Scholar
• Runic R, Lockwood CJ, LaChapelle L, Dipasquale B, De- mopoulos RI, Kumar A et al. Apoptosis and Fas expression in human fetal membranes. J Clin Endocrinol Metab 1998; 83: 660–6.
   Google Scholar
• Smith SC, Baker PN, Symonds EM. Increased placental apoptosis in intrauterine growth restriction. Am J Obstet Gynecol 1997; 177: 1395–401.
   Google Scholar
• Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P. The death domain kinase RIP mediates the TNF- induced NF-kappaB signal. Immunity 1998; 8: 297–303.
   Google Scholar
• Tsao CY, Mendell JR, Luquette M, Dixon B, Morrow G 3rd. Mitochondrial DNA depletion in children. J Child Neurol 2000; 15: 822–4.
   Google Scholar
• Olson JM, Asakura A, Suider L, Hawks R, Strand A, Stoeck J et al. Neurod2 is necessary for deveopment and survival of central nervous system neurons. Dev Biol 2001; 234: 174–87.
   Google Scholar